Imagine if your doctor could tell exactly which antidepressant will work for you by looking at your gut bacteria and genes, rather than using trial and error. This project builds a smart tool that connects brain activity and biological markers to predict drug success. It's like a personalized GPS for mental health treatment to avoid the long road of ineffective medications.
Current antidepressant treatments have a very low success rate, with only 6% of patients achieving remission. Doctors lack the biomarkers needed to choose the right drug for the right patient the first time.
An AI/ML predictive tool for antidepressant efficacy and a patient empowerment Chatbot for data collection.
If you are a drug developer dealing with low remission rates—currently not more than 6% of patients benefit from the therapeutic journey—this project developed an AI/ML predictive tool that identifies new molecular targets for personalized treatment.
If you are a tech provider dealing with poor patient adherence in mental health—this project developed a patient empowerment Chatbot that translates patient stories into usable data for clinicians.
If you are a lab dealing with a lack of early biomarkers for depression—this project developed a multi-omics analysis method covering metagenomics and epigenomics to improve diagnostic accuracy.
Based on available project data, there is no information regarding the pricing or cost of the predictive tool.
The project is already testing across 10 countries and recruiting 350 patients from 6 different countries, suggesting a design intended for international scalability.
Based on available project data, specific IP and licensing terms are not disclosed in the project summary.
The project period runs from 2022-12-01 to 2027-05-31.
The tool integrates real-time EEG, cognitive assessments, and biological samples (blood, stool, saliva) to support the decision-making process of healthcare providers.
The consortium is well-balanced for commercialization, featuring 14 partners across 10 countries. With a 36% industry ratio (5 industrial partners, 5 of which are SMEs), there is a strong bridge between the 3 universities and 3 research centers and the actual market, ensuring the AI tool is developed with commercial viability in mind.
Contact Fondazione EBRIS in Italy for partnership inquiries.
Contact us to explore licensing opportunities for the OPADE AI predictive tool.
